Smith Group Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Smith Group Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,642	Closed	-$375K	–	183
2025 Q4	$375K	Buy	2,642 +382	+17%	+$55.3K	0.02%	154
2025 Q3	$317K	Buy	+2,260	New	+$306K	0.02%	158
2024 Q2	–	Sell	-48,114	Closed	-$6.64M	–	171
2024 Q1	$6.64M	Sell	48,114 -20,340	-30%	-$2.78M	0.38%	70
2023 Q4	$9.02M	Buy	+68,454	New	+$7.88M	0.52%	67
2016 Q2	–	Sell	-17,720	Closed	-$701K	–	506
2016 Q1	$701K	Sell	17,720 -150	-0.8%	-$5.95K	0.02%	161
2015 Q4	$1.01M	Buy	+17,870	New	+$908K	0.03%	173

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smith Group Asset Management's NBIX Position: Q1 2026 in Review

Smith Group Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,642 shares — an estimated $375K sold.

Smith Group Asset Management first reported a position in NBIX in Q4 2015 and held it in 6 quarters. The position peaked at $9.02M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Smith Group Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Smith Group Asset Management sold 2,642 Neurocrine Biosciences shares in Q1 2026, an estimated $375K.
Smith Group Asset Management first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 6 quarters.
Smith Group Asset Management's Neurocrine Biosciences position peaked at $9.02M in Q4 2023.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Smith Group Asset Management's 13F filing for Q1 2026, filed 18 May 2026.